Endocrinology and Metabolism

Original Articles

Mineral, Bone & Muscle
Carnitine Metabolite as a Potential Circulating Biomarker for Sarcopenia in Men: Je Hyun Seo, Jung-Min Koh, Han Jin Cho, Hanjun Kim, Young‑Sun Lee, Su Jung Kim, Pil Whan Yoon, Won Kim, Sung Jin Bae, Hong-Kyu Kim, Hyun Ju Yoo, Seung Hun Lee; Endocrinol Metab. 2025;40(1):93-102. Published online November 28, 2024; DOI: https://doi.org/10.3803/EnM.2024.2117

1,318 View
72 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Sarcopenia, a multifactorial disorder involving metabolic disturbance, suggests potential for metabolite biomarkers. Carnitine (CN), essential for skeletal muscle energy metabolism, may be a candidate biomarker. We investigated whether CN metabolites are biomarkers for sarcopenia.
Methods
Associations between the CN metabolites identified from an animal model of sarcopenia and muscle cells and sarcopenia status were evaluated in men from an age-matched discovery (72 cases, 72 controls) and a validation (21 cases, 47 controls) cohort.
Results
An association between CN metabolites and sarcopenia showed in mouse and cell studies. In the discovery cohort, plasma C5-CN levels were lower in sarcopenic men (P=0.005). C5-CN levels in men tended to be associated with handgrip strength (HGS) (P=0.098) and were significantly associated with skeletal muscle mass (P=0.003). Each standard deviation increase in C5-CN levels reduced the odds of low muscle mass (odd ratio, 0.61; 95% confidence interval [CI], 0.42 to 0.89). The area under the receiver operating characteristic curve (AUROC) of CN score using a regression equation of C5-CN levels, for sarcopenia was 0.635 (95% CI, 0.544 to 0.726). In the discovery cohort, addition of CN score to HGS significantly improved AUROC from 0.646 (95% CI, 0.575 to 0.717; HGS only) to 0.727 (95% CI, 0.643 to 0.810; P=0.006; HGS+CN score). The improvement was confirmed in the validation cohort (AUROC=0.563; 95% CI, 0.470 to 0.656 for HGS; and AUROC=0.712; 95% CI, 0.569 to 0.855 for HGS+CN score; P=0.027).
Conclusion
C5-CN, indicative of low muscle mass, is a potential circulating biomarker for sarcopenia in men. Further studies are required to confirm these results and explore sarcopenia-related metabolomic changes.

Hypothalamus and pituitary gland
Genetic Landscape and Clinical Manifestations of Multiple Endocrine Neoplasia Type 1 in a Korean Cohort: A Multicenter Retrospective Analysis: Boram Kim, Seung Hun Lee, Chang Ho Ahn, Han Na Jang, Sung Im Cho, Jee-Soo Lee, Yu-Mi Lee, Su-Jin Kim, Tae-Yon Sung, Kyu Eun Lee, Woochang Lee, Jung-Min Koh, Moon-Woo Seong, Jung Hee Kim; Endocrinol Metab. 2024;39(6):956-964. Published online November 18, 2024; DOI: https://doi.org/10.3803/EnM.2024.2008

1,636 View
63 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by tumors in multiple endocrine organs, caused by variants in the MEN1 gene. This study analyzed the clinical and genetic features of MEN1 in a Korean cohort, identifying prevalent manifestations and genetic variants, including novel variants.
Methods
This multicenter retrospective study reviewed the medical records of 117 MEN1 patients treated at three tertiary centers in Korea between January 2012 and September 2022. Patient demographics, tumor manifestations, outcomes, and MEN1 genetic testing results were collected. Variants were classified using American College of Medical Genetics and Genomics (ACMG) and French Oncogenetics Network of Neuroendocrine Tumors propositions (TENGEN) guidelines.
Results
A total of 117 patients were enrolled, including 55 familial cases, with a mean age at diagnosis of 37.4±15.3 years. Primary hyperparathyroidism was identified as the most common presentation (84.6%). The prevalence of gastroenteropancreatic neuroendocrine tumor and pituitary neuroendocrine tumor (PitNET) was 77.8% (n=91) and 56.4% (n=66), respectively. Genetic testing revealed 61 distinct MEN1 variants in 101 patients, with 18 being novel. Four variants were reclassified according to the TENGEN guidelines. Patients with truncating variants (n=72) exhibited a higher prevalence of PitNETs compared to those with non-truncating variants (n=25) (59.7% vs. 36.0%, P=0.040).
Conclusion
The association between truncating variants and an increased prevalence of PitNETs in MEN1 underscores the importance of genetic characterization in guiding the clinical management of this disease. Our study sheds light on the clinical and genetic characteristics of MEN1 among the Korean population.

Adrenal gland
The Modified S-GRAS Scoring System for Prognosis in Korean with Adrenocortical Carcinoma: Sun Kyung Baek, Seung Hun Lee, Seung Shin Park, Chang Ho Ahn, Sung Hye Kong, Won Woong Kim, Yu-Mi Lee, Su Jin Kim, Dong Eun Song, Tae-Yon Sung, Kyu Eun Lee, Jung Hee Kim, Kyeong Cheon Jung, Jung-Min Koh; Endocrinol Metab. 2024;39(5):803-812. Published online September 25, 2024; DOI: https://doi.org/10.3803/EnM.2024.2086

1,430 View
71 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Adrenocortical carcinomas (ACCs) are rare tumors with aggressive but varied prognosis. Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score, based on clinical and pathological factors, was found to best stratify the prognosis of European ACC patients. This study assessed the prognostic performance of modified S-GRAS (mS-GRAS) scores including modified grade (mG) by integrating mitotic counts into the Ki67 index (original grade), in Korean ACC patients.
Methods
Patients who underwent surgery for ACC between January 1996 and December 2022 at three medical centers in Korea were retrospectively analyzed. mS-GRAS scores were calculated based on tumor stage, mG (Ki67 index or mitotic counts), resection status, age, and symptoms. Patients were divided into four groups (0–1, 2–3, 4–5, and 6–9 points) based on total mS-GRAS score. The associations of each variable and mS-GRAS score with recurrence and survival were evaluated using Cox regression analysis, Harrell’s concordance index (C-index), and the Kaplan–Meier method.
Results
Data on mS-GRAS components were available for 114 of the 153 patients who underwent surgery for ACC. These 114 patients had recurrence and death rates of 61.4% and 48.2%, respectively. mS-GRAS score was a significantly better predictor of recurrence (C-index=0.829) and death (C-index=0.747) than each component (P<0.05), except for resection status. mS-GRAS scores correlated with shorter progression-free survival (P=8.34E-24) and overall survival (P=2.72E-13).
Conclusion
mS-GRAS scores showed better prognostic performance than tumor stage and grade in Asian patients who underwent surgery for ACC.

Mineral, Bone & Muscle
Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea: Yumie Rhee, Dong-Gune Chang, Jeonghoon Ha, Sooa Kim, Yusun Lee, Euna Jo, Jung-Min Koh; Endocrinol Metab. 2022;37(3):497-505. Published online June 3, 2022; DOI: https://doi.org/10.3803/EnM.2022.1427

9,483 View
342 Download
9 Web of Science
11 Crossref

Abstract PDF PubReader ePub

Background
The efficacy and safety of denosumab have been established in a phase 3, randomized, placebo-controlled trial in Korean postmenopausal women with osteoporosis. This postmarketing surveillance study was aimed to investigate the safety and effectiveness of denosumab in Korean real-world clinical practice.
Methods
Patients with osteoporosis who had received denosumab per the Korean approved indications in the postmarketing setting between September 2014 and September 2019 were enrolled. The primary endpoint was the incidence of adverse events (AEs) and adverse drug reactions (ADRs). The secondary endpoint was the percent change from baseline in bone mineral density (BMD) of the lumbar spine, total hip, and femoral neck.
Results
Of the 3,221 patients enrolled, 3,185 were included in the safety analysis set; 2,973 (93.3%) were female, and the mean± standard deviation (SD) age was 68.9±9.9 years. The mean±SD study period was 350.0±71.4 days. AEs, fatal AEs, and ADRs occurred in 19.3%, 0.8%, and 1.6%, respectively. The most frequent AEs, occurring in >0.5% of patients, were dizziness (0.7%), arthralgia (0.7%), back pain (0.6%), and myalgia (0.6%). Hypocalcemia occurred in 0.3% of patients. There were no cases of osteonecrosis of the jaw and atypical femoral fracture. Mean±SD percent change from baseline in BMD of the lumbar spine, total hip, and femoral neck was 7.3%±23.6%, 3.6%±31.4%, and 3.2%±10.7%, respectively.
Conclusion
The safety and effectiveness of denosumab in Korean patients with osteoporosis in this study were comparable with those in the Korean randomized controlled trial, with no new safety findings.

Citations

Citations to this article as recorded by

Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek
Endocrinology and Metabolism.2025; 40(1): 47. CrossRef
Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection
Anna Spångeus, Johan Rydetun, Mischa Woisetschläger
Osteoporosis International.2024; 35(1): 173. CrossRef
Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
Huei-Kai Huang, Albert Tzu-Ming Chuang, Tzu-Chi Liao, Shih-Chieh Shao, Peter Pin-Sung Liu, Yu-Kang Tu, Edward Chia-Cheng Lai
JAMA Network Open.2024; 7(2): e2354734. CrossRef
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
Yue He, Rong Zhang, Huarui Shen, Yingqi Liu
Frontiers in Pharmacology.2024;[Epub] CrossRef
Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years
Jeongmin Lee, Youn-Ju Lee, Jeonghoon Ha
Journal of Bone Metabolism.2024; 31(3): 246. CrossRef
Adverse Effects of Denosumab in Kidney Transplant Recipients: A 20-Year Retrospective Single-Center Observation Study in Central Taiwan
Tsung-Yin Tsai, Zi-Hong You, Shang-Feng Tsai, Ming-Ju Wu, Tung-Min Yu, Ya-Wen Chuang, Yung-Chieh Lin, Ya-Lian Deng, Chiann-Yi Hsu, Cheng-Hsu Chen
Transplantation Proceedings.2023; 55(4): 837. CrossRef
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
Endocrinology and Metabolism.2023; 38(2): 260. CrossRef
Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
Chaiho Jeong, Jinyoung Kim, Jeongmin Lee, Yejee Lim, Dong-Jun Lim, Ki-Hyun Baek, Jeonghoon Ha
Journal of Clinical Medicine.2023; 12(21): 6904. CrossRef
Denosumab

Reactions Weekly.2022; 1919(1): 221. CrossRef
Denosumab, an effective osteoporosis treatment option for men
Sung Hye Kong
The Korean Journal of Internal Medicine.2022; 37(5): 947. CrossRef

Adrenal Gland
Outcome-Based Decision-Making Algorithm for Treating Patients with Primary Aldosteronism: Jung Hee Kim, Chang Ho Ahn, Su Jin Kim, Kyu Eun Lee, Jong Woo Kim, Hyun-Ki Yoon, Yu-Mi Lee, Tae-Yon Sung, Sang Wan Kim, Chan Soo Shin, Jung-Min Koh, Seung Hun Lee; Endocrinol Metab. 2022;37(2):369-382. Published online April 14, 2022; DOI: https://doi.org/10.3803/EnM.2022.1391

5,983 View
181 Download
7 Web of Science
7 Crossref

Abstract PDF PubReader ePub

Background
Optimal management of primary aldosteronism (PA) is crucial due to the increased risk of cardiovascular and cerebrovascular diseases. Adrenal venous sampling (AVS) is the gold standard method for determining subtype but is technically challenging and invasive. Some PA patients do not benefit clinically from surgery. We sought to develop an algorithm to improve decision- making before engaging in AVS and surgery in clinical practice.
Methods
We conducted the ongoing Korean Primary Aldosteronism Study at two tertiary centers. Study A involved PA patients with successful catheterization and a unilateral nodule on computed tomography and aimed to predict unilateral aldosterone-producing adenoma (n=367). Study B involved similar patients who underwent adrenalectomy and aimed to predict postoperative outcome (n=330). In study A, we implemented important feature selection using the least absolute shrinkage and selection operator regression.
Results
We developed a unilateral PA prediction model using logistic regression analysis: lowest serum potassium level ≤3.4 mEq/L, aldosterone-to-renin ratio ≥150, plasma aldosterone concentration ≥30 ng/mL, and body mass index <25 kg/m2 (area under the curve, 0.819; 95% confidence interval, 0.774 to 0.865; sensitivity, 97.6%; specificity, 25.5%). In study B, we identified female, hypertension duration <5 years, anti-hypertension medication <2.5 daily defined dose, and the absence of coronary artery disease as predictors of clinical success, using stepwise logistic regression models (sensitivity, 94.2%; specificity, 49.3%). We validated our algorithm in the independent validation dataset (n=53).
Conclusion
We propose this new outcome-driven diagnostic algorithm, simultaneously considering unilateral aldosterone excess and clinical surgical benefits in PA patients.

Citations

Citations to this article as recorded by

Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort
Jun Yang, Jacopo Burrello, Jessica Goi, Martin Reincke, Christian Adolf, Evelyn Asbach, Denise Brűdgam, Qifu Li, Ying Song, Jinbo Hu, Shumin Yang, Fumitoshi Satoh, Yoshikiyo Ono, Renata Libianto, Michael Stowasser, Nanfang Li, Qing Zhu, Namki Hong, Drishy
The Lancet Diabetes & Endocrinology.2025; 13(2): 119. CrossRef
Bridging Global and Local Perspectives on Primary Aldosteronism
Ohk-Hyun Ryu
Endocrinology and Metabolism.2025; 40(2): 195. CrossRef
Subtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Ji Won Yoon, Jung Hee Kim
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e788. CrossRef
Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung
The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef
Predicting the resolution of hypertension following adrenalectomy in primary aldosteronism: Controversies and unresolved issues a narrative review
Luigi Marzano
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Prognostic models to predict complete resolution of hypertension after adrenalectomy in primary aldosteronism: A systematic review and meta‐analysis
Luigi Marzano, Amir Kazory, Faeq Husain‐Syed, Claudio Ronco
Clinical Endocrinology.2023; 99(1): 17. CrossRef
2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung
Endocrinology and Metabolism.2023; 38(6): 597. CrossRef

Response

Adrenal Gland
Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age (Endocrinol Metab 2021;36:401-12, Seung Hun Lee et al.): Seung Hun Lee, Jong Woo Kim, Hyun-Ki Yoon, Jung-Min Koh, Chan Soo Shin, Sang Wan Kim, Jung Hee Kim; Endocrinol Metab. 2021;36(4):914-915. Published online August 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.402

3,858 View
87 Download
2 Crossref

PDF PubReader ePub

Citations

Citations to this article as recorded by

Strategies for subtyping primary aldosteronism
Yun-Hsuan Yang, Yu-Ling Chang, Bo-Ching Lee, Ching-Chu Lu, Wei-Ting Wang, Ya-Hui Hu, Han-Wen Liu, Yung-Hsiang Lin, Chin-Chen Chang, Wan-Chen Wu, Fen-Yu Tseng, Yen-Hung Lin, Vin-Cent Wu, Chii-Min Hwu
Journal of the Formosan Medical Association.2024; 123: S114. CrossRef
Diagnostic consistency between computed tomography and adrenal vein sampling of primary aldosteronism: Leading to successful curative outcome after adrenalectomy: A retrospective study
Byung-Chang Kim, Hyun-Ki Yoon, Kye Jin Park, Gun Ha Kim, Shin Jeong Pak, Douk Kwon, Jae Won Cho, Won Woong Kim, Yu-mi Lee, Jung-Min Koh, Seung Hun Lee, Ki-Wook Chung, Tae-Yon Sung
International Journal of Surgery.2023;[Epub] CrossRef

Original Articles

Adrenal Gland
Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism: Ye Seul Yang, Seung Hun Lee, Jung Hee Kim, Jee Hee Yoo, Jung Hyun Lee, Seo Young Lee, A Ram Hong, Dong-Hwa Lee, Jung-Min Koh, Jae Hyeon Kim, Sang Wan Kim; Endocrinol Metab. 2021;36(4):875-884. Published online August 11, 2021; DOI: https://doi.org/10.3803/EnM.2021.1047

6,771 View
167 Download
8 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Adrenal venous sampling (AVS) is performed to distinguish the subtype of primary aldosteronism (PA). The clinical implication of contralateral suppression (CS; aldosterone/cortisol_nondominantperipheral) at AVS remains unclear. We aimed to investigate the clinical significance of CS and its impact on postoperative outcomes after unilateral adrenalectomy.
Methods
In this retrospective observational multi-center study, we analyzed PA patients who underwent both successful adrenocorticotropin hormone-stimulated AVS and unilateral adrenalectomy. Successful cannulation was defined as the selectivity index (cortisol_adrenal/ cortisol_peripheral) ≥3. Clinical and biochemical outcomes after unilateral adrenalectomy were evaluated based on the international Primary Aldosteronism Surgical Outcome consensus.
Results
Among 263 patients analyzed, 247 had CS (93.9%). Patients with CS had lower serum potassium levels, higher plasma aldosterone concentration, higher aldosterone-to-renin ratio (ARR), and larger adenoma size than those without CS. Those with CS showed significantly higher lateralization index than those without CS (P<0.001). Although postoperative blood pressure and ARR significantly decreased in those with CS, clinical and biochemical outcomes were comparable in both groups. When the cut-off value of age was determined using receiver operating characteristic (ROC) analysis, patients aged ≥50 years old with contralateral suppression index (CSI; the ratio between aldosterone/cortisol_nondominant and aldosterone/cortisol_peripheral) ≤0.26 had greater odds ratio (6.43; 95% confidence interval, 1.30 to 31.69) of incident chronic kidney disease than those aged <50 years with CSI >0.26 after adjusting for other factors.
Conclusion
CS may not predict postoperative clinical and biochemical outcomes in subjects with unilateral aldosterone excess, but it is associated with postsurgical deterioration of renal function in subjects over 50 years with CSI ≤0.26.

Citations

Citations to this article as recorded by

Treatment decision based on unilateral index from nonadrenocorticotropic hormone-stimulated and adrenocorticotropic hormone-stimulated adrenal vein sampling in primary aldosteronism
Xizi Zhang, Xiaoyu Shu, Feifei Wu, Jun Yang, Qingfeng Cheng, Zhipeng Du, Ying Song, Yi Yang, Jinbo Hu, Yue Wang, Qifu Li, Shumin Yang
Journal of Hypertension.2024; 42(3): 450. CrossRef
Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung
The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef
Development of a multivariate model predictive of post-adrenalectomy renal function decline in patients with primary aldosteronism: a large-cohort single-center study
Wenhao Lin, Juping Zhao, Chen Fang, Wei He, Xin Huang, Fukang Sun, Jun Dai
World Journal of Urology.2024;[Epub] CrossRef
Prognostic value of contralateral suppression on kidney function after surgery in patients with primary aldosteronism
Nathalie Voss, Sara Mørup, Caroline Clausen, Claus larsen Feltoft, Jan Viberg Jepsen, Mads Hornum, Mikkel Andreassen, Jesper Krogh
Clinical Endocrinology.2023; 98(3): 306. CrossRef
Factors Predicting Long-term Estimated Glomerular Filtration Rate Decrease, a Reliable Indicator of Renal Function After Adrenalectomy in Primary Aldosteronism
Qiyu He, Zhimin Tan, Yu Liu, Liang Zhou
Endocrine Practice.2023; 29(3): 199. CrossRef
Prognostic value of contralateral suppression for remission after surgery in patients with primary aldosteronism
Sara Mørup, Nathalie Voss, Caroline Clausen, Claus Larsen Feltoft, Mikkel Andreassen, Jesper Krogh
Clinical Endocrinology.2022; 96(6): 793. CrossRef
Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism (Endocrinol Metab 2021;36:875-84, Ye Seul Yang et al.)
Zhimin Tan, Qiyu He, Liang Zhou
Endocrinology and Metabolism.2022; 37(6): 951. CrossRef
Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism (Endocrinol Metab 2021;36:875-84, Ye Seul Yang et al.)
Ye Seul Yang, Sang Wan Kim
Endocrinology and Metabolism.2022; 37(6): 953. CrossRef

Clinical Study
Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age: Seung Hun Lee, Jong Woo Kim, Hyun-Ki Yoon, Jung-Min Koh, Chan Soo Shin, Sang Wan Kim, Jung Hee Kim; Endocrinol Metab. 2021;36(2):401-412. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.901

6,342 View
174 Download
21 Web of Science
18 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Guidelines by the Endocrine Society Guideline on bypassing adrenal vein sampling (AVS) in patients <35 years old with marked primary aldosteronism (PA) (hypokalemia and elevated plasma aldosterone concentration [PAC]) and a unilateral lesion on computed tomography (CT) are based on limited number of studies. We aimed to determine the accuracy of CT in PA patients according to age.
Methods
In this retrospective study, we investigated the concordance between CT and AVS in 466 PA patients from two tertiary centers who successfully underwent AVS.
Results
CT had an overall accuracy of 64.4% (300/466). In the group with unilateral lesion, patients with hypokalemia had higher concordance than those without hypokalemia (85.0% vs. 43.6%, P<0.001). In the group with marked PA (hypokalemia and PAC >15.9 ng/dL) and unilateral lesion, accuracy of CT was 84.6% (11/13) in patients aged <35 years; 100.0% (20/20), aged 35 to 39 years; 89.4% (59/66), aged 40 to 49 years; and 79.8% (79/99), aged ≥50 years. Cut-off age and PAC for concordance was <50 years and >29.6 ng/dL, respectively. The significant difference in accuracy of CT in 198 patients with marked PA and a unilateral lesion between the <50-year age group and ≥50-year age group (90.9% vs. 79.8%, P=0.044) disappeared in 139 of 198 patients with PAC > 30.0 ng/dL (91.9% vs. 87.7%, P=0.590).
Conclusion
Patients with hypokalemia, PAC >30.0 ng/dL, and unilateral lesion were at high risk of unilateral PA regardless of age.

Citations

Citations to this article as recorded by

Adrenal Vein Sampling for Primary Aldosteronism: Recommendations From the Australian and New Zealand Working Group
Jun Yang, Damon A. Bell, Richard Carroll, Cherie Chiang, Diane Cowley, Emma Croker, James C. G. Doery, Marianne Elston, Paul Glendenning, Julie Hetherington, Andrea R. Horvath, Shanshan Lu‐Shirzad, Elisabeth Ng, Amanda Mather, Nimalie Perera, Muddassir Ra
Clinical Endocrinology.2025; 102(1): 31. CrossRef
Predicting Bilateral Subtypes of Primary Aldosteronism Without Adrenal Vein Sampling: A Systematic Review and Meta-analysis
Elisabeth Ng, Stella May Gwini, Winston Zheng, Peter J Fuller, Jun Yang
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e837. CrossRef
Subtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Ji Won Yoon, Jung Hee Kim
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e788. CrossRef
Imaging Concordance With Vein Sampling for Primary Aldosteronism: A Cohort Study and Literature Review
Sara Cartwright, MaKayla Gordon, Jessica Shank, Abbey Fingeret
Journal of Surgical Research.2024; 296: 1. CrossRef
Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung
The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef
Temporal trends in clinical features of patients with primary aldosteronism over 20 years
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim
Hypertension Research.2024; 47(8): 2019. CrossRef
Best Practices: Indications and Procedural Controversies of Adrenal Vein Sampling for Primary Aldosteronism
Keith B. Quencer, Abhilasha Singh, Anu Sharma
American Journal of Roentgenology.2023; 220(2): 190. CrossRef
Accuracy of Gallium-68 Pentixafor Positron Emission Tomography–Computed Tomography for Subtyping Diagnosis of Primary Aldosteronism
Jinbo Hu, Tingting Xu, Hang Shen, Ying Song, Jun Yang, Aipin Zhang, Haoyuan Ding, Naiguo Xing, Zhuoyuan Li, Lin Qiu, Linqiang Ma, Yi Yang, Zhengping Feng, Zhipeng Du, Wenwen He, Yue Sun, Jun Cai, Qifu Li, Yue Chen, Shumin Yang, Mei Mei, Suxin Luo, Kangla
JAMA Network Open.2023; 6(2): e2255609. CrossRef
Adrenal Vein Sampling in the Young – Necessary or Not?
Eleftheria Gkaniatsa, Oskar Ragnarsson
Experimental and Clinical Endocrinology & Diabetes.2023; 131(07/08): 435. CrossRef
2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung
Endocrinology and Metabolism.2023; 38(6): 597. CrossRef
Indices of ACTH‐stimulated adrenal venous sampling as predictors of postsurgical outcomes in primary aldosteronism
Seung Hun Lee, Jong Woo Kim, Hyun‐Ki Yoon, Sang Wan Kim, Su Jin Kim, Kyu Eun Lee, Yu‐Mi Lee, Tae‐Yon Sung, Suck Joon Hong, Chan Soo Shin, Jung‐Min Koh, Jung Hee Kim
Clinical Endocrinology.2022; 96(4): 521. CrossRef
Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism
Chang Ho Ahn, Hee Young Na, So Yeon Park, Hyeong Won Yu, Su‐Jin Kim, June Young Choi, Kyu Eun Lee, Sang Wan Kim, Kyeong Cheon Jung, Jung Hee Kim
Clinical Endocrinology.2022; 96(1): 30. CrossRef
Letter to the Editor From Singhania et al: “Increasing Incidence of Primary Aldosteronism in Western Sweden During 3 Decades—Yet an Underdiagnosed Disorder”
Pankaj Singhania, Rana Bhattacharjee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(3): e1315. CrossRef
Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism
Ying Song, Jun Yang, Hang Shen, Elisabeth Ng, Peter J. Fuller, Zhengping Feng, Jinbo Hu, Linqiang Ma, Yi Yang, Zhipeng Du, Yue Wang, Ting Luo, Wenwen He, Qifu Li, Fei-Fei Wu, Shumin Yang
Journal of Hypertension.2022; 40(9): 1692. CrossRef
Validation of Existing Clinical Prediction Tools for Primary Aldosteronism Subtyping
Barbora Kološová, Petr Waldauf, Dan Wichterle, Jan Kvasnička, Tomáš Zelinka, Ondřej Petrák, Zuzana Krátká, Lubomíra Forejtová, Jan Kaván, Jiří Widimský, Robert Holaj
Diagnostics.2022; 12(11): 2806. CrossRef
Fully automatic volume measurement of the adrenal gland on CT using deep learning to classify adrenal hyperplasia
Taek Min Kim, Seung Jae Choi, Ji Yeon Ko, Sungwan Kim, Chang Wook Jeong, Jeong Yeon Cho, Sang Youn Kim, Young-Gon Kim
European Radiology.2022; 33(6): 4292. CrossRef
Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age (Endocrinol Metab 2021;36:401-12, Seung Hun Lee et al.)
Seung Hun Lee, Jong Woo Kim, Hyun-Ki Yoon, Jung-Min Koh, Chan Soo Shin, Sang Wan Kim, Jung Hee Kim
Endocrinology and Metabolism.2021; 36(4): 914. CrossRef
Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age (Endocrinol Metab 2021;36:401-12, Seung Hun Lee et al.)
Pankaj Singhania
Endocrinology and Metabolism.2021; 36(4): 912. CrossRef

Clinical Study
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study: Ki-Hyun Baek, Yoon-Sok Chung, Jung-Min Koh, In Joo Kim, Kyoung Min Kim, Yong-Ki Min, Ki Deok Park, Rajani Dinavahi, Judy Maddox, Wenjing Yang, Sooa Kim, Sang Jin Lee, Hyungjin Cho, Sung-Kil Lim; Endocrinol Metab. 2021;36(1):60-69. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.848

9,711 View
453 Download
13 Web of Science
18 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis.
Methods
Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤–2.5 at the lumbar spine, total hip, or femoral neck) were randomized (1:1) to receive monthly subcutaneous injections of romosozumab (210 mg; n=34) or placebo (n=33) for 6 months.
Results
At month 6, the difference in the least square (LS) mean percent change from baseline in lumbar spine BMD (primary efficacy endpoint) between the romosozumab (9.5%) and placebo (–0.1%) groups was significant (9.6%; 95% confidence interval, 7.6 to 11.5; P<0.001). The difference in the LS mean percent change from baseline was also significant for total hip and femoral neck BMD (secondary efficacy endpoints). After treatment with romosozumab, the percent change from baseline in procollagen type 1 N-terminal propeptide transiently increased at months 1 and 3, while that in C-terminal telopeptide of type 1 collagen showed a sustained decrease. No events of cancer, hypocalcemia, injection site reaction, positively adjudicated atypical femoral fracture or osteonecrosis of the jaw, or positively adjudicated serious cardiovascular adverse events were observed. At month 9, 17.6% and 2.9% of patients in the romosozumab group developed binding and neutralizing antibodies, respectively.
Conclusion
Treatment with romosozumab for 6 months was well tolerated and significantly increased lumbar spine, total hip, and femoral neck BMD compared with placebo in Korean postmenopausal women with osteoporosis (ClinicalTrials.gov identifier NCT02791516).

Citations

Citations to this article as recorded by

Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Shih-Hao Cheng, William Chu, Wen-Hsiang Chou, Woei-Chyn Chu, Yi-No Kang
Drug Safety.2025; 48(1): 7. CrossRef
Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw
Kyeongho Lee, Kihun Kim, June Yeon Kim, Jin‐Woo Kim, Young‐Hoon Kang, Yun Hak Kim, Sung‐Jin Kim
Oral Diseases.2025; 31(4): 1073. CrossRef
Effect of precise health management combined with physical rehabilitation on bone biomarkers in senile osteoporosis patients
Litao Chen, Xiaojing Yan, Yongjian Liu, Yongbin Pei, Jin Zhou, Lei Zhang, Zhixing Du
Scientific Reports.2025;[Epub] CrossRef
Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy
Jung Yoon Park, Hyoung Moo Park, Jae-Yen Song, Kyung Jin Hwang, Mee-Ran Kim, Youn-Jee Chung
Journal of Clinical Medicine.2025; 14(9): 2958. CrossRef
Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis
Bartolomé Lladó Ferrer, Marina Soledad Moreno Garcia, Sara Rojas Herrera, César Antonio Egües Dubuc, Gonzalo Mariscal, Juan Buades Mateu
JCR: Journal of Clinical Rheumatology.2025;[Epub] CrossRef
Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
Takaomi Kobayashi, Megumi Hara, Chisato Shimanoe, Tadatsugu Morimoto, Mawatari Masaaki, Koji Ito, Takafumi Shimazaki
Journal of Bone and Mineral Metabolism.2024; 42(5): 492. CrossRef
Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis
Ronald Man Yeung Wong, Pui Yan Wong, Chaoran Liu, Hei Yuet Wong, Man Ki Fong, Ning Zhang, Wing Hoi Cheung, Sheung Wai Law
Journal of Orthopaedic Translation.2024; 48: 107. CrossRef
Romosozumab for the treatment of osteoporosis – a systematic review
V.-N. Mäkinen, A. S. Sølling, M. McClung, B. L. Langdahl
Journal of Endocrinological Investigation.2024; 48(3): 547. CrossRef
A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang, Guanghui Chen
Expert Opinion on Drug Safety.2023; 22(4): 339. CrossRef
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials (CDM‐J)
Wenbo Huang, Masashi Nagao, Naohiro Yonemoto, Sen Guo, Takeshi Tanigawa, Yuji Nishizaki
Pharmacoepidemiology and Drug Safety.2023; 32(6): 671. CrossRef
Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
Seo-Yong Choi, Jeong-Min Kim, Sang-Hyeon Oh, Seunghyun Cheon, Jee-Eun Chung
Korean Journal of Clinical Pharmacy.2023; 33(2): 128. CrossRef
Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part I)
E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez
SurgiColl.2023;[Epub] CrossRef
Romosozumab in osteoporosis: yesterday, today and tomorrow
Dong Wu, Lei Li, Zhun Wen, Guangbin Wang
Journal of Translational Medicine.2023;[Epub] CrossRef
Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review
Frideriki Poutoglidou, Efthimios Samoladas, Nikolaos Raikos, Dimitrios Kouvelas
Journal of Clinical Densitometry.2022; 25(3): 401. CrossRef
Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
Yun Sun Lee, So Jeong Park, Jin Young Lee, Eunah Choi, Beom-Jun Kim
The Korean Journal of Internal Medicine.2022; 37(4): 821. CrossRef
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
I. R. Reid
Expert Opinion on Drug Safety.2022; 21(12): 1441. CrossRef
Proxied Therapeutic Inhibition on Wnt Signaling Antagonists and Risk of Cardiovascular Diseases: Multi-Omics Analyses
Yu Qian, Cheng-Da Yuan, Saber Khederzadeh, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Ke-Qi Liu, Lin Xu, David Karasik, Shu-Yang Xie, Hou-Feng Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef
Multi-Omics Analyses Identify Pleiotropy and Causality Between Circulating Sclerostin and Atrial Fibrillation
Yu Qian, Peng-Lin Guan, Saber Khederzadeh, Ke-Qi Liu, Cheng-Da Yuan, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Lin Xu, David Karasik, Shu-Yang Xie, sheng zhifeng, Hou-Feng Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef

Review Article

Bone Metabolism
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures: Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh; Endocrinol Metab. 2020;35(1):55-63. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.55

7,347 View
140 Download
20 Web of Science
18 Crossref

Abstract PDF PubReader ePub

Osteoporotic fracture (OF) is associated with high disability and morbidity rates. The burden of OF may be reduced by early identification of subjects who are vulnerable to fracture. Although the current fracture risk assessment model includes clinical risk factors (CRFs) and bone mineral density (BMD), its overall ability to identify individuals at high risk for fracture remains suboptimal. Efforts have therefore been made to identify potential biomarkers that can predict the risk of OF, independent of or combined with CRFs and BMD. This review highlights the emerging biomarkers of bone metabolism, including sphongosine-1-phosphate, leucine-rich repeat-containing 17, macrophage migration inhibitory factor, sclerostin, receptor activator of nuclear factor-κB ligand, and periostin, and the importance of biomarker risk score, generated by combining these markers, in enhancing the accuracy of fracture prediction.

Citations

Citations to this article as recorded by

Bone mineral density in French adults with early-treated phenylketonuria
Elisa Dybal, François Maillot, François Feillet, Alain Fouilhoux, Leonardo Astudillo, Christian Lavigne, Jean-Baptiste Arnoux, Sylvie Odent, Claire Gay, Manuel Schiff, Karin Mazodier, Alice Kuster, Vincent Rigalleau, Christel Thauvin-Robinet, Vanessa Legu
Molecular Genetics and Metabolism.2025; 144(3): 109044. CrossRef
The Impact of Traditional Chinese Medicines on Osteoclastogenesis through NF-κB Signaling Pathway: A Review
Jiajun Huang, Diyou Wu, Yu Zhao, Yun Xue, Junqing Huang, Bin Yang
Pharmacognosy Magazine.2025;[Epub] CrossRef
Global knowledge mapping of receptor activator of nuclear factor kappa-B ligand in osteoporotic fractures: a bibliometric analysis (2001–2024)
Shuai Lu, Huaishuang Shen, Minjuan Li, Yiming Luo, Hao Sun, Xian Zhao, Jianming Chen, Ruifeng Bai, Pengli Han, Yejun Zha, Xieyuan Jiang
Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice
Weihang Gao, Jiao Jiao Li, Jingyu Shi, Hongbing Lan, Yuanyuan Guo, Dehao Fu
Journal of Nanobiotechnology.2024;[Epub] CrossRef
Changes in bone turnover markers 6–12 months after bariatric surgery
Per G. Farup
Scientific Reports.2024;[Epub] CrossRef
Imaging bone turnover assessment through volumetric density-adjusted standardized uptake value using quantitative bone SPECT/CT in osteoporosis
Dong Yun Lee, Jungsu S. Oh, Ji Wan Kim, Seung Hun Lee, Beom-Jun Kim, Jung-Min Koh, Jae Seung Kim, Jin-Sook Ryu
EJNMMI Research.2024;[Epub] CrossRef
The administration of bovine hydroxyapatite-alendronate implant accelerates bone defect healing in an osteoporotic rat
Toetik Aryani, Aniek Setiya Budiatin, Samirah, Aulia Maulidina, Aulia Intan Firdaus, Maria Apriliani Gani, Khoirotin Nisak, Junaidi Khotib, Alvi Jauharotus Syukriya
Technology and Health Care.2023; 31(5): 1747. CrossRef
Impact of Intravenous Iron Substitution on Serum Phosphate Levels and Bone Turnover Markers—An Open-Label Pilot Study
Alexandra Struppe, Jakob E. Schanda, Andreas Baierl, Paul Watzl, Christian Muschitz
Nutrients.2023; 15(12): 2693. CrossRef
Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
Vladimir Gerov, Daniela Gerova, Ilina Micheva, Miglena Nikolova, Galya Mihaylova, Bistra Galunska
Journal of Clinical Medicine.2023; 12(13): 4440. CrossRef
Impact of vitamin D supplementation on markers of bone turnover: Systematic review and meta‐analysis of randomised controlled trials
Mohammad Hassan Sohouli, Sicong Wang, Faisal Almuqayyid, Mariana Papini Gabiatti, Fateme Mozaffari, Zahra Mohamadian, Nazanin Koushki, Kamar Allayl Alras, Abdullah M. AlHossan, Saud K. Albatati, Aya Alfardous Alazm, Saeed Baradwan, Mihnea‐Alexandru Găman,
European Journal of Clinical Investigation.2023;[Epub] CrossRef
Night shift work and serum markers of bone turnover in male shift workers
Margherita Martelli, Gianmaria Salvio, Raffaella Lazzarini, Marijana Milinkovic, Alessandro Ciarloni, Giancarlo Balercia, Lory Santarelli, Massimo Bracci
Chronobiology International.2023; 40(9): 1270. CrossRef
Circulating sRANKL, Periostin, and Osteopontin as Biomarkers for the Assessment of Activated Osteoclastogenesis in Myeloma Related Bone Disease
Vladimir Gerov, Daniela Gerova, Ilina Micheva, Miglena Nikolova, Milena Pasheva, Neshe Nazifova, Bistra Galunska
Cancers.2023; 15(23): 5562. CrossRef
Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide
Subhashis Pal, Shivani Sharma, Konica Porwal, Mohammed Riyazuddin, Chirag Kulkarni, Sourav Chattopadhyay, Sabyasachi Sanyal, Jiaur R. Gayen, Naibedya Chattopadhyay
Calcified Tissue International.2022; 111(2): 196. CrossRef
Serum sclerostin levels in osteoporotic fracture patients
Erwin A. Gorter, Casper R. Reinders, Pieta Krijnen, Natasha M. Appelman-Dijkstra, Inger B. Schipper
European Journal of Trauma and Emergency Surgery.2022; 48(6): 4857. CrossRef
Elevated gamma-glutamyl transpeptidase level is associated with an increased risk of hip fracture in postmenopausal women
Kyoung Jin Kim, Namki Hong, Min Heui Yu, Seunghyun Lee, Sungjae Shin, Sin Gon Kim, Yumie Rhee
Scientific Reports.2022;[Epub] CrossRef
Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
Alice Wang, Nishi Karunasinghe, Lindsay D. Plank, Shuotun Zhu, Sue Osborne, Charis Brown, Karen Bishop, Tiffany Schwass, Sofian Tijono, Michael Holmes, Jonathan Masters, Roger Huang, Christine Keven, Lynnette R. Ferguson, Ross Lawrenson
Scientific Reports.2021;[Epub] CrossRef
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho, Yoon-Kyoung Sung
Endocrinology and Metabolism.2021; 36(3): 536. CrossRef
Nobiletin promotes osteogenic differentiation of human osteoblastic cell line (MG-63) through activating the BMP-2/RUNX-2 signaling pathway
Ying Pang, Lili Liu, Hong Mu, Vishnu Priya Veeraraghavan
Saudi Journal of Biological Sciences.2021; 28(9): 4916. CrossRef

Namgok Lecture 2017

Adrenal gland
Bone Health in Adrenal Disorders: Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh; Endocrinol Metab. 2018;33(1):1-8. Published online March 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.1.1

7,067 View
57 Download
14 Web of Science
13 Crossref

Abstract PDF PubReader ePub

Secondary osteoporosis resulting from specific clinical disorders may be potentially reversible, and thus continuous efforts to find and adequately treat the secondary causes of skeletal fragility are critical to ameliorate fracture risk and to avoid unnecessary treatment with anti-osteoporotic drugs. Among the hyperfunctional adrenal masses, Cushing's syndrome, pheochromocytoma, and primary aldosteronism are receiving particularly great attention due to their high morbidity and mortality mainly by increasing cardiovascular risk. Interestingly, there is accumulating experimental and clinical evidence that adrenal hormones may have direct detrimental effects on bone metabolism as well. Thus, the present review discusses the possibility of adrenal disorders, especially focusing on pheochromocytoma and primary aldosteronism, as secondary causes of osteoporosis.

Citations

Citations to this article as recorded by

A Correlative Study of Bone Metabolism Markers and Primary Aldosteronism
晓彤潘
Advances in Clinical Medicine.2025; 15(05): 656. CrossRef
High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
Clinical Gastroenterology and Hepatology.2022; 20(5): e1022. CrossRef
Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Cancers.2022; 14(8): 1967. CrossRef
Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis
Anning Wang, Yuhan Wang, Hongzhou Liu, Xiaodong Hu, Jiefei Li, Huaijin Xu, Zhimei Nie, Lingjing Zhang, Zhaohui Lyu
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion
Mara Carsote
Diagnostics.2022; 12(11): 2772. CrossRef
Elemental profiling of adrenal adenomas in solid tissue and blood samples by ICP-MS and ICP-OES
Jovana Jagodić, Branislav Rovčanin, Đurđa Krstić, Ivan Paunović, Vladan Živaljević, Dragan Manojlović, Aleksandar Stojsavljević
Microchemical Journal.2021; 165: 106194. CrossRef
Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim
Endocrinology and Metabolism.2021; 36(4): 865. CrossRef
Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service
Jung Hee Kim, Hyemi Moon, Junghyun Noh, Juneyoung Lee, Sin Gon Kim
Endocrinology and Metabolism.2020; 35(1): 157. CrossRef
Pheochromocytoma and paraganglioma: An emerging cause of secondary osteoporosis
Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Tazuru Fukumoto, Yayoi Matsuda, Hiromi Nagata, Masatoshi Ogata, Hisaya Kawate, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa
Bone.2020; 133: 115221. CrossRef
Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
Christian Adolf, Leah T. Braun, Carmina T. Fuss, Stefanie Hahner, Heike Künzel, Laura Handgriff, Lisa Sturm, Daniel A. Heinrich, Holger Schneider, Martin Bidlingmaier, Martin Reincke
Endocrine.2020; 69(3): 625. CrossRef
Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis
Shaomin Shi, Chunyan Lu, Haoming Tian, Yan Ren, Tao Chen
Frontiers in Endocrinology.2020;[Epub] CrossRef
Understanding and managing secondary osteoporosis
Luciano Colangelo, Federica Biamonte, Jessica Pepe, Cristiana Cipriani, Salvatore Minisola
Expert Review of Endocrinology & Metabolism.2019; 14(2): 111. CrossRef
Evaluation of bone health in patients with adrenal tumors
Shobana Athimulam, Irina Bancos
Current Opinion in Endocrinology, Diabetes & Obesity.2019; 26(3): 125. CrossRef

Special Article

Clinical Guidelines for the Management of Adrenal Incidentaloma: Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo; Endocrinol Metab. 2017;32(2):200-218. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.200

22,273 View
821 Download
94 Web of Science
95 Crossref

Abstract PDF PubReader

An adrenal incidentaloma is an adrenal mass found in an imaging study performed for other reasons unrelated to adrenal disease and often accompanied by obesity, diabetes, or hypertension. The prevalence and incidence of adrenal incidentaloma increase with age and are also expected to rise due to the rapid development of imaging technology and frequent imaging studies. The Korean Endocrine Society is promoting an appropriate practice guideline to meet the rising incidence of adrenal incidentaloma, in cooperation with the Korean Adrenal Gland and Endocrine Hypertension Study Group. In this paper, we discuss important core issues in managing the patients with adrenal incidentaloma. After evaluating core proposition, we propose the most critical 20 recommendations from the initially organized 47 recommendations by Delphi technique.

Citations

Citations to this article as recorded by

Outcomes after adrenalectomy in elderly patients; a propensity score matched analysis
Charlotte L. Viëtor, Inge S. van Egmond, Gaston J. H. Franssen, Cornelis Verhoef, Richard A. Feelders, Tessa M. van Ginhoven
Updates in Surgery.2025; 77(1): 183. CrossRef
Digital Phenotyping of Rare Endocrine Diseases Across International Data Networks and the Effect of Granularity of Original Vocabulary
Seunghyun Lee, Namki Hong, Gyu Seop Kim, Jing Li, Xiaoyu Lin, Sarah Seager, Sungjae Shin, Kyoung Jin Kim, Jae Hyun Bae, Seng Chan You, Yumie Rhee, Sin Gon Kim
Yonsei Medical Journal.2025; 66(3): 187. CrossRef
Use of natural language processing to retrospectively identify and improve follow-up of adrenal incidentalomas based on patient and nodule characteristics
Lillie Grace Veazey, Christopher Wu, Zhixing Song, Haleigh Negrete, Srini Tridandapani, Herbert Chen, Andrea Gillis, Jessica Fazendin, John D. Osborne, Brenessa Lindeman
The American Journal of Surgery.2025; 242: 116199. CrossRef
Two-Stage Deep Learning Model for Adrenal Nodule Detection on CT Images: A Retrospective Study
Chang Ho Ahn, Taewoo Kim, Kyungmin Jo, Seung Shin Park, Min Joo Kim, Ji Won Yoon, Taek Min Kim, Sang Youn Kim, Jung Hee Kim, Jaegul Choo
Radiology.2025;[Epub] CrossRef
Evaluation of the Adrenal Mass in Urologic Practice
Jackson Schmidt, Marshall Strother
Urologic Clinics of North America.2025; 52(2): 181. CrossRef
The impact of mild autonomous cortisol secretion and proposed interventions
María Bernarda Iriarte-Durán, Sara Donato, Aura Herrera, Arturo Vega, José María Jiménez Casinello, Mónica Marazuela, Marta Araujo-Castro
Expert Review of Endocrinology & Metabolism.2025; : 1. CrossRef
Imaging of Adrenal Incidentalomas: What Actually Happens in Everyday Clinical Practice?
Brian Ngo, Tracy Liu, Eddie Lau
Journal of Medical Imaging and Radiation Oncology.2025;[Epub] CrossRef
Adrenal incidentaloma: Prevalence and evaluation. Experiences from a single health network
Mitchell Munnings, Shaun Koh, Christopher Gilfillan
Endocrine and Metabolic Science.2025; 18: 100238. CrossRef
The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
Lily Owei, Heather Wachtel
Annals of Surgical Oncology.2025;[Epub] CrossRef
Our Surgical Treatment Results for Suprarenal Masses: Single-Center Study
İbrahim Halil Öcal, Ömer Başol, Hüseyin Bilge
Medical Records.2025; 7(2): 361. CrossRef
Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient
Yusaku Yoshida, Kiyomi Horiuchi, Michio Otsuki, Takahiro Okamoto
Surgery Today.2024; 54(12): 1417. CrossRef
The improvement of postoperative blood pressure and associated factors in patients with hormone‐negative adrenal adenoma and hypertension
Jiaxing Sun, Yingchun Dong, Hanbo Wang, Xudong Guo, Ning Suo, Shangjian Li, Xiangbin Ren, Shaobo Jiang
Journal of Surgical Oncology.2024; 129(6): 1073. CrossRef
Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study
Xiaojiang Zhu, Saisai Liu, Yimin Yuan, Nannan Gu, Jintong Sha, Yunfei Guo, Yongji Deng
BMC Pediatrics.2024;[Epub] CrossRef
Mineral metabolism assays and osteoporotic fracture risk evaluation in menopausal population diagnosed with adrenal incidentalomas: a sub-analysis of PRECES study
Alexandra-Ioana Trandafir, Mihaela Stanciu, Ana Valea, Oana-Claudia Sima, Claudiu Nistor, Mădălina Gabriela Iliescu, Ileana Ciobanu, Florina Ligia Popa, Mara Carsote
Balneo and PRM Research Journal.2024; 15(Vol.15, no): 692. CrossRef
Assessment of the diagnostic efficacy of radiological and functional evaluation of primary adrenal mass and its’ surgical outcomes
Yash Manharlal Tilala, Sabyasachi Panda, Abhilekh Tripathi, Sachin Sharma, Amiya Shankar Paul, Sanjay Choudhuri, Samir Swain
Urologia Journal.2024; 91(4): 674. CrossRef
Demographic and Clinical Characteristics of Patients with Adrenal Incidentaloma from a Single Center in South India: A Retrospective Study
Abhijeet B Jawanjal, Siddarth Sadananda, Nikitha Sriramaneni, Y. P. Ganavi, Pramila Kalra, Chitra Selvan, P. R. Manjunath, Praneethi K. Shetty
Annals of African Medicine.2024; 23(4): 567. CrossRef
Quantitative imaging biomarkers in the assessment of adrenal nodules
Mariana Yalon, Patrick J. Navin
Abdominal Radiology.2024; 50(5): 2169. CrossRef
Clinical and Radiological Features of Atypical Adrenal Masses—A Multicenter Retrospective Study
Vania Balderrama-Brondani, Ruaa Al-Ward, Katja Kiseljak-Vassiliades, Lauren Fishbein, Danielle Dawes, Oksana Hamidi, Reza Pishdad, Juan Pablo Perdomo Rodriguez, Mohamad Anas Sukkari, Joseph R Grajo, Hans Kumar Ghayee, Sara Bedrose, Roland L Bassett, Amir
The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Characterizing incidental mass lesions in abdominal dual-energy CT compared to conventional contrast-enhanced CT
Jack Junchi Xu, Peter Sommer Ulriksen, Camilla Wium Bjerrum, Michael Patrick Achiam, Timothy Andrew Resch, Lars Lönn, Kristoffer Lindskov Hansen
Acta Radiologica.2023; 64(3): 945. CrossRef
Metastatic Adrenal PEComa: Case Report and Short Review of the Literature
Enrico Battistella, Luca Pomba, Marica Mirabella, Michele Gregianin, Antonio Scapinello, Marco Volante, Antonio Toniato
Medicina.2023; 59(1): 149. CrossRef
Surgical management and outcomes of spinal metastasis of malignant adrenal tumor: A retrospective study of six cases and literature review
Xiangzhi Ni, Jing Wang, Jiashi Cao, Kun Zhang, Shuming Hou, Xing Huang, Yuanjin Song, Xin Gao, Jianru Xiao, Tielong Liu
Frontiers in Oncology.2023;[Epub] CrossRef
An adrenal incidentaloma that had appeared to produce dehydroepiandrosterone-sulfate in excess before immunohistochemical study of the tumor
Toshihide Yamamoto, Takuma Kimura, Yuki Kubo, Shin-ichi Nakatsuka, Hiromasa Harada, Takashi Suzuki, Hironobu Sasano
Endocrine Journal.2023; 70(1): 43. CrossRef
Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study
Albin Kjellbom, Ola Lindgren, Malin Danielsson, Henrik Olsen, Magnus Löndahl
The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): e536. CrossRef
Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study
Mingzhen Li, Xiaoying Duan, Di You, Linlin Liu
Frontiers in Medicine.2023;[Epub] CrossRef
Primary Aldosteronism Prevalence – An Unfolding Story
Suranut Charoensri, Adina F. Turcu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(07/08): 394. CrossRef
Management of Adrenal Cortical Adenomas: Assessment of Bone Status in Patients with (Non-Functioning) Adrenal Incidentalomas
Alexandra-Ioana Trandafir, Mihaela Stanciu, Simona Elena Albu, Vasile Razvan Stoian, Irina Ciofu, Cristian Persu, Claudiu Nistor, Mara Carsote
Journal of Clinical Medicine.2023; 12(13): 4244. CrossRef
Clinical manifestations of functionally autonomous cortisol secretion in patients with adrenal masse
T. R. Chzhen, T. P. Kiseleva
Ural Medical Journal.2023; 22(3): 13. CrossRef
Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?
M. Caputo, T. Daffara, A. Ferrero, M. Romanisio, E. Monti, C. Mele, M. Zavattaro, S. Tricca, A. Siani, A. Clemente, C. Palumbo, S. De Cillà, A. Carriero, A. Volpe, P. Marzullo, G. Aimaretti, F. Prodam
Journal of Endocrinological Investigation.2023; 47(2): 377. CrossRef
Adrenal ganglioneuroma: Features and outcomes of cases series
Pei Li, Rongchang Zhang, Guang Wang, Jiongming Li
Asian Journal of Surgery.2023; 46(11): 5272. CrossRef
Recent Updates on the Management of Adrenal Incidentalomas
Seung Shin Park, Jung Hee Kim
Endocrinology and Metabolism.2023; 38(4): 373. CrossRef
Adrenal malakoplakia a rare lesion that mimics a neoplasm
Orión Erenhú Rodríguez González, Jesus Eduardo Osorio, Edgar Iván Bravo Castro
Urology Case Reports.2023; 51: 102568. CrossRef
LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines
Jongsung Noh, Chaelin Lee, Jung Hee Kim, Seung Woon Myung, Man Ho Choi
Journal of Lipid Research.2023; 64(11): 100453. CrossRef
Incidentaloma adrenal. Del hallazgo casual al diagnóstico definitivo
Mercedes Retamal Ortíz, Ana Belén Vicario Parada, Elena Vázquez Jarén
Actualización en Medicina de Familia.2023;[Epub] CrossRef
Can MDCT Enhancement Patterns Be Helpful in Differentiating Secretory from Non-Functional Adrenal Adenoma?
Svetlana Kocic, Vladimir Vukomanovic, Aleksandar Djukic, Jovica Saponjski, Dusan Saponjski, Vuk Aleksic, Vesna Ignjatovic, Katarina Vuleta Nedic, Vladan Markovic, Radisa Vojinovic
Medicina.2023; 60(1): 72. CrossRef
Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA
Neal E. Rowe, Ravi Kumar, Nicola Schieda, Ferhan Siddiqi, Thomas McGregor, Kristen McAlpine, Philippe Violette, Varun Bathini, Michael Eng, Jason Izard
Journal of Urology.2023; 210(4): 590. CrossRef
Computer-assisted Reporting and Decision Support Increases Compliance with Follow-up Imaging and Hormonal Screening of Adrenal Incidentalomas
Renata R. Almeida, Bernardo C. Bizzo, Ramandeep Singh, Katherine P. Andriole, Tarik K. Alkasab
Academic Radiology.2022; 29(2): 236. CrossRef
Incidental Adrenal Masses: Adherence to Guidelines and Methods to Improve Initial Follow-Up: A Systematic Review
Timothy Feeney, Andrea Madiedo, Philip E. Knapp, Avneesh Gupta, David McAneny, Frederick Thurston Drake
Journal of Surgical Research.2022; 269: 18. CrossRef
Incidental Adrenal Lesions May Not Always Require Further Imaging Work-up
Deborah A. Baumgarten
Radiology.2022; 302(1): 138. CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy
Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee
Radiology.2022; 302(1): 129. CrossRef
Management of incidental adrenal nodules: a survey of abdominal radiologists conducted by the Society of Abdominal Radiology Disease-Focused Panel on Adrenal Neoplasms
Michael T. Corwin, Nicola Schieda, Erick M. Remer, Elaine M. Caoili
Abdominal Radiology.2022; 47(4): 1360. CrossRef
Primary hyperaldosteronism: indications for screening
Novella M. Chikhladze
Terapevticheskii arkhiv.2022; 94(1): 107. CrossRef
Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas
Jordan A. Higgs, Alyssa P. Quinn, Kevin D. Seely, Zeke Richards, Shad P. Mortensen, Cody S. Crandall, Amanda E. Brooks
International Journal of Molecular Sciences.2022; 23(8): 4340. CrossRef
Can Radiomics Provide Additional Diagnostic Value for Identifying Adrenal Lipid-Poor Adenomas From Non-Adenomas on Unenhanced CT?
Binhao Zhang, Huangqi Zhang, Xin Li, Shengze Jin, Jiawen Yang, Wenting Pan, Xue Dong, Jin Chen, Wenbin Ji
Frontiers in Oncology.2022;[Epub] CrossRef
Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor Boards
Costanza Chiapponi, Daniel Pinto Dos Santos, Milan Janis Michael Hartmann, Matthias Schmidt, Michael Faust, Roger Wahba, Christiane Josephine Bruns, Anne Maria Schultheis, Hakan Alakus
Hormone and Metabolic Research.2022; 54(05): 294. CrossRef
Optimal and novel imaging of the adrenal glands
Patrick J. Navin, Michael R. Moynagh
Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(3): 253. CrossRef
Adrenal Tumors in Young Adults: Case Reports and Literature Review
Małgorzata Zdrojewska, Emilia Mech-Siebieszuk, Renata Świątkowska-Stodulska, Bartosz Regent, Michał Kunc, Łukasz Zdrojewski, Krzysztof Sworczak
Medicina.2022; 58(6): 746. CrossRef
Incidence of malignancy in adrenal nodules detected on staging CTs of patients with potentially resectable colorectal cancer
Hae Young Kim, Yoon Jin Lee, Won Chang, Ji Hoon Park, Jungheum Cho, Hyeon Jeong Oh, Young Hoon Kim, Kyoung Ho Lee
European Radiology.2022; 32(12): 8560. CrossRef
Appendiceal Incidentalomas: Prevalence, Radiographic Characteristics, Management, and Outcomes
Adam Kelly, Stacy O’Connor, Diana Kane, Chiang-Ching Huang, Harveshp Mogal
Annals of Surgical Oncology.2022; 29(13): 8265. CrossRef
Laparoscopic large adrenal mass resection: why we should be more careful?
Mohsen Varyani, Mahmood Parvin, Hamidreza Akbari Gilani
African Journal of Urology.2022;[Epub] CrossRef
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
Nadia Sawicka-Gutaj, Hanna Komarowska, Dawid Gruszczyński, Aleksandra Derwich, Anna Klimont, Marek Ruchała
Journal of Clinical Medicine.2022; 11(19): 5563. CrossRef
Application of radiomics in adrenal incidentaloma: a literature review
Cheng Li, Yan Fu, Xiaoping Yi, Xiao Guan, Longfei Liu, Bihong T. Chen
Discover Oncology.2022;[Epub] CrossRef
Hormone-inactive adrenal tumors in clinician’s practice
T. R. Chzhen, T. P. Kiseleva
Perm Medical Journal.2022; 39(5): 48. CrossRef
The diagnostic value of salivary cortisol and salivary cortisone in patients with suspected hypercortisolism
Vendela Berndt, Per Dahlqvist, Jennie de Verdier, Henrik Ryberg, Oskar Ragnarsson
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Role of Intraoperative Indocyanine Green (ICG) and Preoperative 3-Dimensional (3D) Reconstruction in Laparoscopic Adrenalectomy: A Propensity Score-matched Analysis
Giuseppe Palomba, Vincenza Paola Dinuzzi, Francesca Pegoraro, Roberto Ivan Troisi, Roberto Montalti, Giovanni Domenico De Palma, Giovanni Aprea
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022; 32(6): 643. CrossRef
The Etiological Profile of Adrenal Incidentalomas
Fatima-Zahra Lahmamssi, Loubna Saadaoui, Hayat Aynaou, Houda Salhi, Hanan El Ouahabi
Cureus.2022;[Epub] CrossRef
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinology and Metabolism.2022; 37(6): 851. CrossRef
Conduite à tenir face à un fortuitome surrénalien chez le chien ou le chat
Diane Pichard, Ghita Benckekroun
Le Nouveau Praticien Vétérinaire canine & féline.2022; 19(82): 40. CrossRef
Laparoscopic transperitoneal adrenalectomy: a comparative study of different techniques for vessel sealing
Luca Cardinali, Edlira Skrami, Elisa Catani, Flavia Carle, Monica Ortenzi, Andrea Balla, Mario Guerrieri
Surgical Endoscopy.2021; 35(2): 673. CrossRef
Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study
Chang Ho Ahn, Jung Hee Kim, Man Young Park, Sang Wan Kim
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1362. CrossRef
Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review
Marta Araujo-Castro, Pablo Valderrábano, Héctor F. Escobar-Morreale, Felicia A. Hanzu, Gregori Casals
Endocrine.2021; 72(1): 40. CrossRef
A Rare Neoplasm: Primary Adrenal Leiomyosarcoma
Jack T. Barnett, Christine W. Liaw, Reza Mehrazin
Urology.2021; 148: e11. CrossRef
Adrenal Ganglioneuroma Presenting as an Incidentaloma in an Adolescent Patient
Sonia G. Sharma, Steven N. Levine, Xin Gu
AACE Clinical Case Reports.2021; 7(1): 61. CrossRef
Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series
Jeongmin Lee, Jeonghoon Ha, Sang-Kuon Lee, Hye Lim Park, Sung-Hoon Kim, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Moo Il Kang, Min-Hee Kim
International Journal of General Medicine.2021; Volume 14: 673. CrossRef
Best Achievements in Pituitary and Adrenal Diseases in 2020
Chang Ho Ahn, Jung Hee Kim
Endocrinology and Metabolism.2021; 36(1): 51. CrossRef
Adrenal surgery: Review of 35 years experience in a single centre
Enrico Battistella, Stefania Ferrari, Luca Pomba, Antonio Toniato
Surgical Oncology.2021; 37: 101554. CrossRef
Adrenocortical Carcinoma: A Case of Missed Diagnosis
Yusef Hazimeh, Carlie Sigel, Carsello Carie, Mathew Leinung, Zaynab Khalaf
Cureus.2021;[Epub] CrossRef
Imagerie fonctionnelle en endocrinologie : nouveaux paradigmes à l’horizon 2020
E. Marchal
Médecine Nucléaire.2021; 45(3): 158. CrossRef
Adrenal Incidentaloma
Caren G. Solomon, Electron Kebebew
New England Journal of Medicine.2021; 384(16): 1542. CrossRef
Can Hematological Parameters Play a Role in the Differential Diagnosis of Adrenal Tumors?
Mehmet Gürkan Arıkan, Göktan Altuğ Öz, Nur Gülce İşkan, Necdet Süt, İlkan Yüksel, Ersan Arda
Uro.2021; 1(2): 39. CrossRef
Incidental Adrenal Nodules
Daniel I. Glazer, Michael T. Corwin, William W. Mayo-Smith
Radiologic Clinics of North America.2021; 59(4): 591. CrossRef
Antioxidant Barrier and Oxidative Damage to Proteins, Lipids, and DNA/RNA in Adrenal Tumor Patients
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Anna Gibała, Anna Starzyńska, Małgorzata Żendzian-Piotrowska, Anna Zalewska, Mateusz Maciejczyk, Jos L. Quiles
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef
Laparoscopic Retroperitoneoscopic Removal of an Adrenal Hemangioma: a Case Report
Kristin McCoy, Katherine Howe, Daniel Tershak
Journal of Endocrine Surgery.2021; 21(3): 70. CrossRef
Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Eu Jeong Ku, Chaelin Lee, Jaeyoon Shim, Sihoon Lee, Kyoung-Ah Kim, Sang Wan Kim, Yumie Rhee, Hyo-Jeong Kim, Jung Soo Lim, Choon Hee Chung, Sung Wan Chun, Soon-Jib Yoo, Ohk-Hyun Ryu, Ho Chan Cho, A Ram Hong, Chang Ho Ahn, Jung Hee Kim, Man Ho Choi
Endocrinology and Metabolism.2021; 36(5): 1131. CrossRef
Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Katarzyna Makarewicz, Anna Zalewska, Mateusz Maciejczyk
Journal of Inflammation Research.2021; Volume 14: 6317. CrossRef
Cirugía laparoscópica en incidentaloma suprarrenal para el cirujano general: serie de casos
Martín Adrián Bolívar-Rodríguez, Marcel Antonio Cázarez-Aguilar, Pedro Alejandro Magaña-Zavala, Francisco Magaña-Olivas, José Martín Niebla-Moreno
Revista Mexicana de Cirugía Endoscópica.2021; 22(1): 8. CrossRef
Adrenal adenomas: what to do with them? Review 2
S. Rybakov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(3): 241. CrossRef
Laparoscopic adrenalectomy for giant adrenal tumours
Alessio Giordano, Giovanni Alemanno, Carlo Bergamini, Andrea Valeri, Paolo Prosperi
Journal of Minimal Access Surgery.2021; 17(1): 76. CrossRef
Is Follow-up of Adrenal Incidentalomas Always Mandatory?
Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, Soraya Puglisi, Massimo Terzolo
Endocrinology and Metabolism.2020; 35(1): 26. CrossRef
Imaging Findings of Primary Adrenal Leiomyosarcoma: A Case Report
Hye Ran Yoon, Dong Hee Park
Journal of the Korean Society of Radiology.2020; 81(2): 459. CrossRef
WFUMB position paper on the management incidental findings: adrenal incidentaloma
Christoph F. Dietrich, Jean Michel Correas, Yi Dong, Christian Nolsoe, Susan Campbell Westerway, Christian Jenssen
Ultrasonography.2020; 39(1): 11. CrossRef
A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features
Takamasa Ichijo, Hajime Ueshiba, Hajime Nawata, Toshihiko Yanase
Endocrine Journal.2020; 67(2): 141. CrossRef
Mimics, pitfalls, and misdiagnoses of adrenal masses on CT and MRI
Khaled M. Elsayes, Mohab M. Elmohr, Sanaz Javadi, Christine O. Menias, Erick M. Remer, Ajaykumar C. Morani, Akram M. Shaaban
Abdominal Radiology.2020; 45(4): 982. CrossRef
Adrenal Incidentaloma
Mark Sherlock, Andrew Scarsbrook, Afroze Abbas, Sheila Fraser, Padiporn Limumpornpetch, Rosemary Dineen, Paul M Stewart
Endocrine Reviews.2020; 41(6): 775. CrossRef
A Web Application for Adrenal Incidentaloma Identification, Tracking, and Management Using Machine Learning
Wasif Bala, Jackson Steinkamp, Timothy Feeney, Avneesh Gupta, Abhinav Sharma, Jake Kantrowitz, Nicholas Cordella, James Moses, Frederick Thurston Drake
Applied Clinical Informatics.2020; 11(04): 606. CrossRef
Presentation and outcome of patients with an adrenal mass: A retrospective observational study
Nadeema Rafiq, Tauseef Nabi, SajadAhmad Dar, Shahnawaz Rasool
Clinical Cancer Investigation Journal.2020; 9(5): 198. CrossRef
Evaluation of Functionality and Growth Rates in Adrenal Incidentalomas: Single Center Experience
Suna AVCI, Yüksel Aslı OZTURKMEN, Sayid ZUHUR, Gulkan OZKAN, Elif GUVEN, Nazan DEMİR, Yuksel ALTUNTAS
Phoenix Medical Journal.2020; 2(3): 125. CrossRef
Percutaneous Adrenal Radiofrequency Ablation: A Short Review for Endocrinologists
Byung Kwan Park
Endocrinology and Metabolism.2020; 35(4): 750. CrossRef
Autonomous cortisol secretion in adrenal incidentalomas
Marta Araujo-Castro, Miguel Antonio Sampedro Núñez, Mónica Marazuela
Endocrine.2019; 64(1): 1. CrossRef
Primary adrenal schwannoma: a series of 31 cases emphasizing their clinicopathologic features and favorable prognosis
Jun Zhou, Dandan Zhang, Wencai Li, Luting Zhou, Haimin Xu, Saifang Zheng, Chaofu Wang
Endocrine.2019; 65(3): 662. CrossRef
Challenging risk factors for right and left laparoscopic adrenalectomy: A single centre experience with 272 cases
Kadir Omur Gunseren, Mehmet Cagatay Cicek, Hakan Vuruskan, Yakup Kordan, Ismet Yavascaoglu
International braz j urol.2019; 45(4): 747. CrossRef
A case report on 111In chloride bone marrow scintigraphy in management of adrenal myelolipoma
Tatsuya Yamamoto, Mitsuru Koizumi, Atsushi Kohno, Noboru Numao, Kentaro Inamura
Medicine.2019; 98(8): e14625. CrossRef
PRACTICAL ASPECTS OF LAPAROSCOPIC ADRENALECTOMY IN CHILDREN WITH BENIGN ADRENAL TUMORS
I. V. Poddubny, R. S. Oganesyan, K. N. Tolstov, M. A. Kareva
Russian Journal of Pediatric Surgery.2019; 23(5): 248. CrossRef
Incidental neuroblastoma with bilateral retinoblastoma: what are the chances?
Kelsey Roelofs, Furqan Shaikh, William Astle, Brenda L. Gallie, Sameh E. Soliman
Ophthalmic Genetics.2018; 39(3): 410. CrossRef
Surgical Considerations in Subclinical Cushing’s Syndrome. When is it Time to Operate?
Alexander M. Nixon, C Aggeli, C Tserkezis, GN Zografos
Hellenic Journal of Surgery.2018; 90(1): 27. CrossRef
Adrenal incidentaloma – diagnostic and treating problem – own experience
Ryszard Pogorzelski, Krzysztof Celejewski, Sadegh Toutounchi, Ewa Krajewska, Tomasz Wołoszko, Małgorzata Szostek, Wawrzyniec Jakuczun, Patryk Fiszer, Małgorzata Legocka, Zbigniew Gałązka
Open Medicine.2018; 13(1): 281. CrossRef

Original Articles

Clinical Study
The Association of Higher Plasma Macrophage Migration Inhibitory Factor Levels with Lower Bone Mineral Density and Higher Bone Turnover Rate in Postmenopausal Women: Hyeonmok Kim, Seong Hee Ahn, Chaeho Shin, Seung Hun Lee, Beom-Jun Kim, Jung-Min Koh; Endocrinol Metab. 2016;31(3):454-461. Published online July 26, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.3.454

4,930 View
46 Download
8 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader

Background

Despite evidence from animal and clinical studies showing the detrimental effects of macrophage migration inhibitory factor (MIF) on bone metabolism, there are no clinical studies relating circulating MIF levels to osteoporosis-related phenotypes. This cross-sectional study investigated the association of plasma MIF with bone mineral density (BMD), bone turnover markers (BTMs), and prevalence of osteoporosis in postmenopausal Korean women.

Methods

A total of 246 women not taking any medications or diagnosed with any diseases that could affect bone metabolism were enrolled. BMD values at the lumbar spine, femoral neck, and total femur, and blood levels of MIF and BTMs were measured in all subjects. Osteoporosis was defined by World Health Organization criteria.

Results

Before and after adjustment for confounding variables, higher MIF levels were significantly associated with lower BMD values at all measured sites and higher levels of all BTMs. All BMD values and BTMs significantly changed in a dose-dependent fashion across increasing MIF quartile. When participants were divided into two groups according to osteoporosis status, postmenopausal women with osteoporosis demonstrated 24.2% higher plasma MIF levels than those without osteoporosis (P=0.041). The odds ratio per each standard deviation increment of MIF levels for prevalent osteoporosis was 1.32 (95% confidence interval, 1.01 to 1.73).

Conclusion

This study provides the first epidemiological evidence that higher plasma MIF may be associated with higher risk of osteoporosis resulting from lower bone mass and higher bone turnover rate, and thus it could be a potential biomarker of poor bone health outcomes in postmenopausal women.

Citations

Citations to this article as recorded by

The role of MIF in periodontitis: A potential pathogenic driver, biomarker, and therapeutic target
Tongfeng Fang, Liu Liu, Dongzhe Song, Dingming Huang
Oral Diseases.2024; 30(3): 921. CrossRef
Variation of Bone Turnover Markers in Childhood and Adolescence
Yiduo Zhang, Jing Zhang, Xiaocui Huang, Xingnan Yu, Ye Li, Fan Yu, Wenjie Zhou, Ziqing Li
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
Elena Schwendich, Laura Salinas Tejedor, Gernot Schmitz, Markus Rickert, Jürgen Steinmeyer, Stefan Rehart, Styliani Tsiami, Jürgen Braun, Xenofon Baraliakos, Jörg Reinders, Elena Neumann, Ulf Müller-Ladner, Silvia Capellino
Cells.2022; 11(10): 1609. CrossRef
Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes
Elisabeth Gjefsen, Kristina Gervin, Guro Goll, Lars Christian Haugli Bråten, Monica Wigemyr, Hans Christian D Aass, Maria Dehli Vigeland, Elina Schistad, Linda Margareth Pedersen, Are Hugo Pripp, Kjersti Storheim, Kaja Kristine Selmer, John Anker Zwart
RMD Open.2021; 7(2): e001726. CrossRef
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
Endocrinology and Metabolism.2020; 35(1): 55. CrossRef
Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis
Mohammed Howait, Abdullah Albassam, Chiaki Yamada, Hajime Sasaki, Laila Bahammam, Mariane Maffei Azuma, Luciano Tavares Angelo Cintra, Abhay R Satoskar, Satoru Yamada, Robert White, Toshihisa Kawai, Alexandru Movila
The Journal of Immunology.2019; 202(7): 2035. CrossRef
Preventive Effects of Low Parathyroid Hormone Levels on Hip Fracture in Patients with Vitamin D Deficiency
Seong-Eun Byun, Soonchul Lee, Ji Wan Kim, Yong-Chan Ha, Chul-Ho Kim, Cheungsoo Ha, Keun Jung Ryu, Jung-Min Koh, Hyung Kyung Kim, Jae Suk Chang
Journal of Bone Metabolism.2019; 26(2): 89. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
New Biological Markers of Bone Metabolism in Osteoporosis Treatment
Sun Wook Cho
Endocrinology and Metabolism.2016; 31(3): 400. CrossRef

Bone Metabolism
Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis: In-Jin Cho, Ho-Yeon Chung, Sung-Woon Kim, Jae-Won Lee, Tae-Won Lee, Hye-Soon Kim, Sin-Gon Kim, Han Seok Choi, Sung-Hee Choi, Chan Soo Shin, Ki-Won Oh, Yong-Ki Min, Jung-Min Koh, Yumie Rhee, Dong-Won Byun, Yoon-Sok Chung, Jeong Hyun Park, Dong Jin Chung, Minho Shong, Eun-Gyoung Hong, Chang Beom Lee, Ki Hyun Baek, Moo-Il Kang; Endocrinol Metab. 2015;30(3):272-279. Published online December 9, 2014; DOI: https://doi.org/10.3803/EnM.2015.30.3.272

5,751 View
51 Download
4 Web of Science
5 Crossref

Abstract PDF PubReader

Background

The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis.

Methods

This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period.

Results

After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment.

Conclusion

The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period.

Citations

Citations to this article as recorded by

Effect of vitamin D supplementation or fortification on bone turnover markers in women: a systematic review and meta-analysis
Nasrin Nasimi, Sanaz Jamshidi, Aida Askari, Nazanin Zolfaghari, Erfan Sadeghi, Mehran Nouri, Nick Bellissimo, Shiva Faghih
British Journal of Nutrition.2024; 131(9): 1473. CrossRef
Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
Dong-Yun Lee, Yoon-Sok Chung
Scientific Reports.2022;[Epub] CrossRef
Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis
So Young Park, Moo-Il Kang, Hyung Moo Park, Yumie Rhee, Seong Hwan Moon, Hyun Koo Yoon, Jung-Min Koh, Jae Suk Chang, In Joo Kim, Ye Yeon Won, Ye Soo Park, Hoon Choi, Chan Soo Shin, Taek Rim Yoon, Sung-Cheol Yun, Ho-Yeon Chung
Archives of Osteoporosis.2020;[Epub] CrossRef
Efficacy and safety of vitamin D3 B.O.N intramuscular injection in Korean adults with vitamin D deficiency
Han Seok Choi, Yoon-Sok Chung, Yong Jun Choi, Da Hea Seo, Sung-Kil Lim
Osteoporosis and Sarcopenia.2016; 2(4): 228. CrossRef
Pharmacologic treatment of osteoporosis
Yong-Ki Min
Journal of the Korean Medical Association.2016; 59(11): 847. CrossRef

First
Prev
Page of 1
Next
Last

Search